Investigating heart problems in patients with fatty liver disease
Official title: Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease
Run by Post Graduate Institute of Medical Education and Research, Chandigarh · NCT06386094 · Data updated 2026-11-12
This study looks at how fatty liver disease might affect heart health in adults aged 18-65 by checking for heart problems like coronary artery disease and heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh Academic / other |
| Locations | 1 site (Chandigarh, Chandigarh) |
| Status | Recruiting |
| Started | July 15, 2023 |
| Main results expected | August 15, 2027 |
| Study ends | November 15, 2027 |
| Registry record updated | January 29, 2025 |
| Trial ID | NCT06386094 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 diagnosed with metabolic dysfunction-associated steatotic liver disease.
✕Probably not a fit
Patients over 65 years old or those with significant cardiac or renal comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between non-alcoholic fatty liver disease (NAFLD) and cardiac dysfunction, particularly focusing on cirrhotic cardiomyopathy. Patients aged 18-65 with a diagnosis of metabolic dysfunction-associated steatotic liver disease will undergo echocardiographic assessments to evaluate the presence of coronary artery disease, arrhythmias, and heart failure. The study seeks to develop a model that links these cardiac issues to the underlying liver condition, addressing a gap in current research regarding the cardiovascular risks associated with NAFLD.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cardiac dysfunction in patients with fatty liver disease, potentially reducing cardiovascular mortality.
How similar studies have gone: While there is emerging research linking NAFLD to cardiac dysfunction, this specific approach to model the relationship is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age range of 18-65 years * metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE). Exclusion Criteria: * Age \>65 years * Chronic renal disease * Pregnancy and peripartum cardiomyopathy * Hypertension * Valvular heart disease * Sick sinus syndrome/ Pacemaker * Cardiac rhythm disorder * Hypothyroidism * Hyperthyroidism * Portal vein thrombosis * Transjugular intrahepatic porto systemic shunt (TIPS) insertion * Hepatocellular carcinoma * Anemia Hb \< 8gm/dl in females, and \< 9 gm/dl in males at the time of assessment
Where it's running
-
Dr. Madhumita Premkumar
Chandigarh, Chandigarh, India Recruiting
Study contacts
- Study coordinator: Madhumita Premkumar
- Email: drmadhumitap@gmail.com
- Phone: 01722754777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD
This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.
-
Ultraportable Hepatoscope ultrasound for measuring liver fat in MASLD/MASH
The Hepatoscope device will be tested to see if it can measure liver fat accurately in adults with MASLD/MASH compared with MRI-PDFF.
-
Evaluating Nicotinamide for Liver Fibrosis in Type 2 Diabetes Patients
This study is testing if a supplement called nicotinamide can help people with type 2 diabetes and liver scarring feel better and improve their liver health.
-
Impact of CoQ10 on patients with fatty liver disease
This study is testing if taking high doses of CoQ10 can help people with fatty liver disease feel better by reducing inflammation and improving their health markers.
-
Non-invasive tool to predict fatty liver disease
This study is testing a new, non-invasive tool to see if it can help identify fatty liver disease in healthy people and those already diagnosed with it.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.